IMMImmutep
About Immutep
Immutep (ASX:IMM) is a clinical-stage biotechnology company that is developing novel LAG-3 (lymphocyte-activation gene 3) targeted immunotherapies for cancer and autoimmune diseases. LAG-3 is a cell surface molecule that acts as a checkpoint inhibitor, regulating the activity of T cells, a type of immune cell that plays a critical role in fighting cancer and disease. Immutep's operations are focused on the development and commercialization of its LAG-3 targeted immunotherapies. The company has a portfolio of three clinical-stage and two earlier-stage product candidates. Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3 protein that is currently in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
What is IMM known for?
Snapshot
Public AU
Ownership
2001
Year founded
45
Employees
New South Wales, Australia
Head office
1 of 424
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Australia
Produtos e/ou serviços de Immutep
- Development of LAG-3 targeted immunotherapies for cancer: Immutep is developing a range of LAG-3 targeted immunotherapies for cancer, including eftilagimod alpha (IMP321), a soluble recombinant LAG-3 protein that acts as an agonist of antigen presenting cells (APCs).
- Development of T cell receptor (TCR) therapies for cancer: Immutep is developing TCR therapies for cancer, including T cell engaging bispecific antibodies (TEBs) that redirect T cells to tumour cells expressing specific tumour antigens.
- Development of bispecific antibody therapies for cancer: Immutep is developing bispecific antibody therapies for cancer, including TEBs and other bispecific antibodies that target different tumour antigens.
- Development of combination therapies for cancer: Immutep is developing combination therapies for cancer, which combine LAG-3 targeted immunotherapies, TCR therapies, and bispecific antibody therapies with other cancer treatments, such as chemotherapy and radiation therapy.
- Licensing of Immutep's technologies to other companies: Immutep licences its technologies to other companies, which allows these companies to develop their own LAG-3 targeted immunotherapies, TCR therapies, and bispecific antibody therapies.
- Provision of consulting and support services to other companies developing cancer immunotherapies: Immutep provides consulting and support services to other companies developing cancer immunotherapies, such as advice on preclinical and clinical development, regulatory strategy, and manufacturing.
equipe executiva do Immutep
- Mr. Marc VoigtCEO, MD, CFO, Chief Business Officer & Executive Director
- Ms. Deanne Miller LLBCOO, General Counsel & Joint Company Secretary
- Dr. Frederic Triebel M.D., Ph.D.Chief Scientific Officer & Executive Director
- Mr. Christian Mueller BBA, MSc.Chief Development Officer
- Dr. Stephan Winckels M.D., Ph.D.Chief Medical Officer
- Ms. Indira NaiduJoint Company Secretary